Agilent Technologies – Consensus ‘Buy’ rating and 17.7% Upside Potential

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Agilent Technologies with ticker code (A) have now 17 market analysts covering the stock. The analyst consensus now points to a rating of ‘Buy’. The range between the high target price and low target price is between $174.00 and $145. calculating the average target price we see $163.06. Now with the previous closing price of $138.50 this would imply there is now a potential upside of 17.7%. Also worth taking note is the 50 day moving average now sits at $139.66 while the 200 day moving average is $139.36. The market cap for the company is $40,949m. Company Website: https://www.agilent.com

The potential market cap would be $48,210m based on the market consensus.

Agilent Technologies provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer’s representatives, and electronic commerce. Agilent Technologies was incorporated in 1999 and is headquartered in Santa Clara, California.

The company has a dividend yield of 0.65% with the ex dividend date set at 3-4-2023 (DMY).

Other points of data to note are a P/E ratio of 31.12, revenue per share of 23.28 and a 10.1% return on assets.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

      Search

      Search